Sandoz Says To High Court: No Violation Of Biologics Price Competition And Innovation Act
WASHINGTON, D.C. — Sandoz Inc. argues in a May 17 brief to the U.S. Supreme Court that an appellate court properly concluded both that Sandoz did not violate the Biologics Price...To view the full article, register now.
Already a subscriber? Click here to view full article